Study of EMB-01 for advanced left-sided colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have left-sided colorectal cancer (from the splenic flexure to the rectum) that has spread or cannot be removed.
- You have had at least one standard treatment for advanced cancer, including chemotherapy and targeted therapy, but it stopped working or caused unacceptable side effects.
- You have not taken TAS-102, fruquintinib, or regorafenib before.
- You are willing to provide a tumor sample from a recent biopsy or one taken in the last 2 years.
- You have no KRAS, NRAS, or BRAF mutations, and your tumor is not HER2 positive or have certain other gene changes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
This trial tests a new drug called EMB-01 combined with standard chemotherapy to treat colorectal cancer that cannot be surgically removed or has spread to other parts of the body. The goal is to see if this combination helps slow or shrink the cancer.
This early-phase trial studies EMB-01 in people with advanced or metastatic gastrointestinal cancers to see how well it works and how safe it is. To join, your tumor’s DNA or protein pattern (especially EGFR or cMET) must match specific lab results, and you must have tried standard treatments.
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.